UK Research & Innovation 

Biomedical catalyst 2021: early and late-stage awards.  UK registered organisations can apply for a share of up to £18 million to develop innovative healthcare products, technologies, and processes. Competition closes: Thursday 26 August 2021 11:00am

Summary: UK registered businesses can apply for a share of up to £18 million to develop innovative healthcare products, technologies and processes. This funding is from Innovate UK, part of UK Research and Innovation. Your project can address: disease prevention and proactive management of health and chronic conditions earlier and better detection and diagnosis of disease, leading to better patient outcomes tailored treatments that either change the underlying disease or offer potential cures. This list is not intended to be exhaustive.

Project total eligible costs must be between £250,000 and £4 million.

See:  https://apply-for-innovation-funding.service.gov.uk/competition/922/overview

————————————————————————————————————————————–

Horizon Europe

Note this EU funding program is likely to present several funding opportunities in health in the coming months. Currently:

Medical Technology and Devices: from Lab to Patient. Scope: EU-funded early-stage Research on novel Medical Technologies and Devices is uncovering unique opportunities to benefits patients and support clinicians.

Medical Technology and Devices businesses are facing long and capital-intensive product development cycles, complex regulatory procedures, slow market uptake requiring the support of key opinion leaders and intensive follow-up with early adopters. In addition to a mature technology, a well thought-out and realistic exploitation path with emphasis on achieving market traction as proof of both clinical and market potential of the idea is needed.

Proposal submitted to this transition challenge call should aim to:

  • Perform the necessary R&D to advance from an existing proof-of-principle technology to a mature version to initiate clinical evaluation.
  • Develop an exploitation strategy, qualitatively and quantitatively outlining the proposed path to patient and describing an investable proposition.
  • Proposal submitted to this call can target any technology addressing important health needs in the direct clinical treatment and care of patients.

EU contribution of up to a EUR 2.5 million and a duration of up to 3 years is appropriate.

Deadline for this single-stage is: 22 September 2021 17:00:00 Brussels time. (Opening date: 19 May 2021).

See: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-eic-2021-transitionchallenges-01